Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 A new report, commissioned by ... takes an in-depth look at Indiana,s ... resulted over two different time frames: 1993 to 2002 ... of future opportunities for investment growth.  The Life ... report shows gains in innovation dollars as well as ...
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... 2014 The “Molecular Diagnostic Market ... Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, ... - Global Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5CU Denver study says upgrading infrastructure could reduce flood damage 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5
... Brings Wealth of Industry Experience, LA JOLLA, Calif., ... company, today announced the,appointment of R. Scott Greer to ... former chairman and CEO of Abgenix, is a seasoned,entrepreneur ... in the,biopharmaceutical industry. "Scott Greer is a stellar ...
... WELLESLEY, Mass., Oct. 8 Coley Pharmaceutical,Group, Inc. ... and,developing a novel class of drug candidates known ... Directors has adopted a Stockholder,Rights Plan (the "Rights ... the Board of Directors to protect Coley,s stockholders. ...
... Emphysema and chronic bronchitis patients to benefit from rapid, ... ... formoterol fumarate -, NAPA, Calif., Oct. ... MYL ), today announced the launch of Perforomist(TM),(formoterol fumarate) Inhalation ...
Cached Biology Technology:Anaptys Biosciences Appoints R. Scott Greer to Board of Directors 2Coley Pharmaceutical Group Adopts Shareholder Rights Plan 2Coley Pharmaceutical Group Adopts Shareholder Rights Plan 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:10/30/2014)... York | Heidelberg, 30 October 2014 Biological membranes ... better understanding of adsorption of solution ions onto ... cells. Now, a new study provides a quantitative ... surrounding solution ions. Joanna Kotyńska and Zbigniew Figaszewski ... authors of a study describing these findings, just ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
(Date:10/29/2014)... the largest study of its kind to date, researchers ... that heighten the risk for autism. Joseph Buxbaum, Ph.D., ... City, Mark Daly, Ph.D., Broad Institute of Harvard and ... samples from affected children, parents and unrelated people. They ... contribute to the risk for autism spectrum disorder (ASD) ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... the MPI of Biochemistry and GSK pursues the objective ... development work is based on the research findings of ... and fellow scientist Mathias Bcker successfully described the role ... in connection with the development of type II diabetes, ...
... on proteins is critical for understanding how cells function ... easy to extract and study, it is far more ... responsible for exchanging elements essential to our health, like ... Now Prof. Nir Ben-Tal and his graduate students Maya ...
... Massachusetts Medical School have uncovered new evidence suggesting that the ... cases of amyotrophic lateral sclerosis (ALS, or Lou Gehrig,s disease), ... Discovery of this common pathology is described in the October ... the SOD1 gene has long been understood to play a ...
Cached Biology News:Cooperation in diabetes research 2Breakthrough: With a chaperone, copper breaks through 2UMMS researchers identify protein associated with sporadic ALS 2UMMS researchers identify protein associated with sporadic ALS 3
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Medium for cryopreserving subcutaneous or omental preadipocytes...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
Biology Products: